Based on the TRACON Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for TRACON Pharmaceuticals Inc is not available over the next 12 months. TRACON Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of TRACON Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 7 negative signals. At the last closing, TRACON Pharmaceuticals Inc’s stock price was USD 0.03. TRACON Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +248.11% over the last year.
No recent analyst target price found for TRACON Pharmaceuticals Inc
No recent average analyst rating found for TRACON Pharmaceuticals Inc
Company Overview TRACON Pharmaceuticals Inc
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. Read Less
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of...Read More
Frequently Asked Questions About TRACON Pharmaceuticals Inc (TCON) Stock
Stock Target Advisor's fundamental analysis for TRACON Pharmaceuticals Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on TCON's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TCON's stock to indicate what its average analyst target is.
TCON stock's Price/Earning ratio is 0.01.
Our analysis grades TCON stock's Price / Earning ratio at A. This means that TCON stock's Price/Earning ratio is above 6.999999999999995% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this TCON may be undervalued for its sector.
The last closing price of TCON's stock was USD 0.03.
The most recent market capitalization for TCON is USD 0.11M.
Unfortunately we do not have enough analyst data on TCON's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains TRACON Pharmaceuticals Inc's stock.
As per our most recent records TRACON Pharmaceuticals Inc has 17 Employees.
TRACON Pharmaceuticals Inc's registered address is 4350 La Jolla Village Drive, San Diego, CA, United States, 92122.
You can get more information about it from TRACON Pharmaceuticals Inc's website at https://www.traconpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About TRACON Pharmaceuticals Inc (TCON) Stock
Stock Target Advisor's fundamental analysis for TRACON Pharmaceuticals Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on TCON's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TCON's stock to indicate what its average analyst target is.
TCON stock's Price/Earning ratio is 0.01.
Our analysis grades TCON stock's Price / Earning ratio at A. This means that TCON stock's Price/Earning ratio is above 6.999999999999995% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this TCON may be undervalued for its sector.
The last closing price of TCON's stock was USD 0.03.
The most recent market capitalization for TCON is USD 0.11M.
Unfortunately we do not have enough analyst data on TCON's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains TRACON Pharmaceuticals Inc's stock.
As per our most recent records TRACON Pharmaceuticals Inc has 17 Employees.
TRACON Pharmaceuticals Inc's registered address is 4350 La Jolla Village Drive, San Diego, CA, United States, 92122.
You can get more information about it from TRACON Pharmaceuticals Inc's website at https://www.traconpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TCON !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
